Compare IHRT & HQL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IHRT | HQL |
|---|---|---|
| Founded | 1974 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Investment Managers |
| Sector | Consumer Discretionary | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 623.2M | 510.2M |
| IPO Year | 2019 | N/A |
| Metric | IHRT | HQL |
|---|---|---|
| Price | $3.94 | $16.73 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $4.50 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 120.9K |
| Earning Date | 02-26-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.56% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.79 |
| Revenue | ★ $3,856,033,000.00 | N/A |
| Revenue This Year | $1.96 | N/A |
| Revenue Next Year | $5.62 | N/A |
| P/E Ratio | ★ N/A | $17.08 |
| Revenue Growth | ★ 1.39 | N/A |
| 52 Week Low | $0.95 | $11.34 |
| 52 Week High | $5.44 | $14.37 |
| Indicator | IHRT | HQL |
|---|---|---|
| Relative Strength Index (RSI) | 43.70 | 47.14 |
| Support Level | $3.88 | $16.15 |
| Resistance Level | $4.19 | $17.29 |
| Average True Range (ATR) | 0.19 | 0.34 |
| MACD | -0.08 | -0.03 |
| Stochastic Oscillator | 9.30 | 52.89 |
iHeartMedia Inc is a United States-based audio media company. The company operates through the segments of the Multiplatform Group, the Digital Audio Group, and the Audio & Media Services Group. The company derives prime revenue from the Multiplatform Group segment which includes the company's Broadcast radio, Networks and Sponsorships, and Events businesses. The Digital Audio Group segment includes all of the company's digital businesses, including podcasting; and the Audio & Media Services Group includes Katz Media Group, a full-service media representation business, and RCS Sound Software, a provider of scheduling and broadcast software and services.
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mostly in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have potential for above-average growth.